{"id":395836,"date":"2022-08-11T00:00:00","date_gmt":"2022-08-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0035-2022-biopharma-metastatic-esophageal-cancer-unmet-need-us-eu-2022\/"},"modified":"2026-04-14T10:20:55","modified_gmt":"2026-04-14T10:20:55","slug":"unneon0035-2022-biopharma-metastatic-esophageal-cancer-unmet-need-us-eu-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0035-2022-biopharma-metastatic-esophageal-cancer-unmet-need-us-eu-2022\/","title":{"rendered":"Metastatic Esophageal Cancer | Unmet Need | US\/EU | 2022"},"content":{"rendered":"<p>Metastatic esophageal cancer remains a subpopulation for which few treatment options exist. For decades, treatment was limited to chemotherapy-based regimens such as FOLFOX and DCF, but the recent approvals of the immune checkpoint inhibitors Keytruda (Merck &#038; Co.) and Opdivo (Bristol Myers Squibb) as single agents and in combination with chemotherapy are beginning to change the treatment landscape. Nevertheless, substantial need remains for more-efficacious treatments for metastatic esophageal cancer, particularly for tumors with low PD-L1 expression.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>How satisfied are U.S. and European medical oncologists with current treatment options for metastatic esophageal cancer?<\/li>\n<li>What are the treatment drivers and goals most likely to influence the choice of therapy for metastatic esophageal cancer?<\/li>\n<li>How do current therapies, such as Keytruda and Opdivo, perform on key clinical attributes, and what are the hidden opportunities for drug developers in this patient population?<\/li>\n<li>What trade-offs are U.S. and European medical oncologists willing to make across key clinical attributes and pricing when considering hypothetical target product profiles for metastatic esophageal cancer?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany.<\/p>\n<p><strong>Primary research: <\/strong>Survey of 62 U.S. and 30 European medical oncologists fielded in April 2022.<\/p>\n<p><strong>Key companies: <\/strong>Bristol Myers Squibb, Merck &#038; Co.<\/p>\n<p><strong>Key drugs:<\/strong> Opdivo, Keytruda, and trastuzumab.<\/p>\n","protected":false},"template":"","class_list":["post-395836","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-esophageal-cancer","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/395836","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/395836\/revisions"}],"predecessor-version":[{"id":576222,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/395836\/revisions\/576222"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=395836"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}